 |
300 West 6th Street, Suite 2250 +1.512.647.1900 |
December 7, 2020
Draft Registration Statement
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re: Confidential Submission of Draft Registration Statement on Form S-1
Ladies and Gentlemen:
On behalf of Ibere Pharmaceuticals, a Cayman Islands exempted company (the “Company”), we hereby confidentially submit the Company’s Draft Registration Statement on Form S-1 pursuant to Title I, Section 106 under the Jumpstart Our Business Startups Act (the “JOBS Act”) and Section 24(b)(2) of the Securities Exchange Act of 1934, as amended, for non-public review by the staff of the Securities and Exchange Commission. The Company is an “emerging growth company” within the meaning of the JOBS Act. Please direct all notices and communications with respect to this confidential submission to each of the following:
| Ibere Pharmaceuticals |
| Attention: Osagie Imasogie |
| 2005 Market Street, Suite 2030 |
| Philadelphia, PA 19103 |
| (267) 765-3222 |
| Email: osagie@phoenixipv.com |
| With a copy to: |
| Shearman & Sterling LLP |
| Attention: Carmelo M. Gordian |
| 300 West 6th Street, Suite 2250 |
| Austin, Texas 78701 |
| (512) 647-1902 |
| Email: carmelo.gordian@shearman.com |
Should you have any questions on this submission, please do not hesitate to contact me at (512) 647-1902.
Very truly yours,
/s/ Carmelo M. Gordian
Carmelo M. Gordian, Partner
Cc: Osagie Imasogie, Ibere Pharmaceuticals
| SHEARMAN.COM |
| Shearman & Sterling LLP is a limited liability partnership organized in the United States under the laws of the state of Delaware, which laws limit the personal liability of partners. |